Navigation Links
YM BioSciences Expands Phase I/II Trial for JAK Inhibitor CYT387
Date:11/18/2010

lopment of a drug that could help these patients," said Dr. Jason Gotlib, Assistant Professor, Department of Medicine (Hematology), Stanford University Medical Center.

CYT387 was granted Orphan Drug Designation by the US FDA in September.

For more information on the CYT387 Phase I/II trial, please go to:
cr="true" href="http://clinicaltrials.gov/ct2/show/NCT00935987?term=cyt387&rank=1">http://clinicaltrials.gov/ct2/show/NCT00935987?term=cyt387&rank=1 Oral Presentation at the 52nd American Society of Hematology Annual Meeting: An oral presentation of the CYT387 Phase I/II results will be delivered by Dr. Pardanani on Monday, December  6, 2010 at 11:15 AM in the Orange County Convention Center, Valencia B/C as part of the session named Myeloproliferative Syndromes: Clinical and Translational Advances in Myeloproliferative Neoplasms. YM will host a conference call following the presentation to discuss the trial results. About YM BioSciences YM BioSciences Inc. is a drug development company advancing three clinical-stage products: CYT387, a small molecule, dual inhibitor of JAK1/JAK2 kinase; nimotuzumab, an EGFR-targeting monoclonal antibody; and CYT997, a potent vascular disrupting agent (VDA).

CYT387 is an orally administered inhibitor of both the JAK1 and JAK2 kinase enzymes, which have been implicated in a number of immune cell disorders including myeloproliferative disorders and inflammatory diseases as well as certain cancers. CYT387 is currently in a Phase I/II trial in myelofibrosis with detailed initial safety and activity data expected at the American Society of Hematology (ASH) meeting in December 2010. Nimotuzumab is a humanized monoclonal antibody targeting EGFR with an enhanced side effect profile. Nimotuzumab is being evaluated in numerous Phase II and III trials worldwide by YM's licensees. CYT997 is an orally-available smal
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Ardea Biosciences to Present at Two Upcoming Investor Conferences
2. YM BioSciences Reports Fiscal First Quarter 2011 Operational and Financial Results
3. YM BIOSCIENCES REPORTS SIGNIFICANT RESPONSE RATES IN ANEMIA, SPLENOMEGALY, AND CONSTITUTIONAL SYMPTOMS FROM THE PHASE I/II TRIAL OF ITS JAK1/JAK2 INHIBITOR, CYT387, IN MYELOFIBROSIS
4. Regado Biosciences Awarded Three Grants from the Federal Government to Advance Research of Lead Programs
5. Sangamo BioSciences Awarded Grants for the Development of Four ZFP Therapeutic® Programs
6. Ardea Biosciences Awarded a $733,438 Grant from the U.S. Government Under the Patient Protection and Affordable Care Act
7. X-BODY BioSciences Awarded Grant for Therapeutic Discovery Project Targeting Metastatic Tumor Stem Cells
8. Ardea Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference
9. Regado Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference in New York City
10. GeneLink BioSciences, Inc. Ranked 62nd Fastest Growing Company in North America on Deloittes 2010 Technology Fast 500™
11. Sangamo BioSciences Announces Third Quarter 2010 Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... HARBOR, Mich. , Sept. 18, 2014  Health Enhancement ... biotech firm investigating early-stage algae bioactive compounds and metabolic processes, ... to the company,s board of directors. Ms. Nola E. ... and investment advisor joined the board effective September 17, 2014. ... Ms. Masterson agree to join our board," states Andrew ...
(Date:9/18/2014)... Texas Governor Rick Perry, Texas ... Health Science Center CEO Brett Giroir, M.D., and ... Human Services (HHS), State of Texas and biopharmaceutical ... vaccine manufacturing facility in Bryan, Texas, which when ... Texas A&M Biocorridor – a rapidly evolving hub ...
(Date:9/18/2014)... 2014 Research and Markets has ... Stem Cell Industry Report, 2014-2017" report to their ... cells that can differentiate into specialized cells and can ... cell therapy can be applied to treatment of cardiovascular ... system diseases, damage or lesion of liver, kidney and ...
(Date:9/18/2014)... Sept. 18, 2014 Research and Markets ... Human Albumin Industry Report 2014" report to their ... Report 2014 is a professional and in-depth study on ... The report provides a basic overview of ... structure. The human albumin market analysis is provided for ...
Breaking Biology Technology:Health Enhancement Announces New Board Member In Advance Of Annual Shareholder Meeting 2Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 2Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 3Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 4Global and Chinese Stem Cell Industry Report, 2014-2017 2Global and Chinese Stem Cell Industry Report, 2014-2017 3Global Human Albumin Industry Report 2014 2Global Human Albumin Industry Report 2014 3
... Institute for Clinical Research, Inc. (PICR) today announced that president and CEO Dr. ... Year ® 2010 Award in San Diego for the second year ... June 9, 2010 at the Hyatt La Jolla Aventine. , ... Dr. Hompesch is being recognized for his establishment and leadership of PICR, ...
... 12 The International Collaborative Cancer Group, in collaboration with the ... Intergroup Exemestane Study (IES).  IES is a randomized, double blind multinational trial ... period of 91 months. Max Neeman will be responsible for ... , , ...
... ... event for experts in detection and identification of biological and chemical threats and will ... identification, and analysis both in the field and at the point-of-care. , ... (PRWEB) May 12, 2010 -- ...
Cached Biology Technology:Profil Institute's Dr. Marcus Hompesch Named Finalist in Ernst & Young Entrepreneur Of The Year(R) 2010 Award for Second Year in a Row 2Profil Institute's Dr. Marcus Hompesch Named Finalist in Ernst & Young Entrepreneur Of The Year(R) 2010 Award for Second Year in a Row 3Max Neeman International Signs Agreement for Data Management/EDC of Large Phase IV Trials from Multiple Sites 2U.S. Department of Homeland Security Keynote to Open 16th Biodetection Technologies Conference Next Month in Arlington, VA 2U.S. Department of Homeland Security Keynote to Open 16th Biodetection Technologies Conference Next Month in Arlington, VA 3
(Date:9/18/2014)... have built the first smartphone app that automatically ... trends. In other words, your smartphone knows your ... -- and how that affects you. , The ... and loneliness to their academic performance, also may ... example, to monitor mental health, trigger intervention and ...
(Date:9/18/2014)... 18, 2014Many Americans across racial and ethnic groups ... impact on their day-to-day life, more so than ... and speech (57% of African-Americans, 49% of non-Hispanic ... When asked which disease or ailment is the ... first among African-Americans followed by AIDS/HIV. Hispanics ...
(Date:9/18/2014)... celebrated tonight at the third annual Golden Goose Award ... premature infants and in paving the way for the ... supported by the National Science Foundation, the National Institutes ... be honored at a ceremony at the Library of ... of Congress will be on hand to help present ...
Breaking Biology News(10 mins):New Dartmouth smartphone app reveals users' mental health, performance, behavior 2New Dartmouth smartphone app reveals users' mental health, performance, behavior 3New Dartmouth smartphone app reveals users' mental health, performance, behavior 4Americans rate losing eyesight as having greatest impact on their lives 2Americans rate losing eyesight as having greatest impact on their lives 33rd annual Golden Goose award ceremony honors 8 researchers; Unusual work had big results 2
... NEW YORK (APRIL 15, 2008) A comprehensive book of ... was released today by the Wildlife Conservation Society. ... on such issues as diseases shared by animals and people; ... as Afghanistan. State of the Wild: A Global Portrait ...
... research demonstrates that novel probe technology based ... force microscopy (AFM) cantilevers for applications such ... and single molecule mechanics measurements. In ... these novel probes simultaneously measure material properties ...
... with high cholesterol in their early 40s are more ... cholesterol, according to research that will be presented at ... Meeting in Chicago, April 1219, 2008. "Our findings ... patients to attack high cholesterol levels in their,40s to ...
Cached Biology News:Wildlife Conservation Society releases definitive 'state of the wild' 2Fast AFM probes measure multiple properties of biomolecules or materials simultaneously 2Fast AFM probes measure multiple properties of biomolecules or materials simultaneously 3
The Holten mini vertical flow workbench provides a particle-free environment for sample protection against airborne contaminants....
...
Medium bottle for hybridization 250 x 35mm...
Request Info...
Biology Products: